Skip to main content
Howard Burris, MD, Oncology, Nashville, TN

HowardABurrisMD

Oncology Nashville, TN

Hematologic Oncology

President, Clinical Operations and Chief Medical Officer, Sarah Cannon

Dr. Burris is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Burris' full profile

Already have an account?

  • Office

    250 25th Ave N
    Ste 100
    Nashville, TN 37203
    Phone+1 615-320-5090

Education & Training

  • San Antonio Uniformed Services Health Education Consortium
    San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 1988 - 1991
  • San Antonio Uniformed Services Health Education Consortium
    San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1985 - 1988
  • University of South Alabama College of Medicine
    University of South Alabama College of MedicineClass of 1985

Certifications & Licensure

  • TN State Medical License
    TN State Medical License 1997 - 2025
  • TX State Medical License
    TX State Medical License 1991 - 2025
  • PA State Medical License
    PA State Medical License 1988 - 1994
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Fellow (FASCO) American Society of Clinical Oncologists, 2010

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Maintenance of health-related quality of life in elderly patients treated with ribociclib + letrozole in MONALEESA-2. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Most Patients Should Be Tested 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
  • 7th Community Oncology Conference 
    Global Academy for Medical Education (Elsevier), Las Vegas, Nevada - 3/30/2012

Press Mentions

  • Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19
    Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19May 29th, 2020
  • New Drugs Make Headway Against Lung, Prostate, Colon Cancers
    New Drugs Make Headway Against Lung, Prostate, Colon CancersMay 29th, 2020
  • Patients with Certain Cancers Are Nearly Three Times as Likely to Die of Covid-19, Study Says
    Patients with Certain Cancers Are Nearly Three Times as Likely to Die of Covid-19, Study SaysApril 28th, 2020
  • Join now to see all

Professional Memberships